Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma

Current Medical Research and Opinion

Volumn 23, Issue 12, 2007, Pages 3113-3122

  Brookman, Laurence J ^a   Knowles, Lisa J ^a   Barbier, Michaela ^b   Elharrar, Brigitte ^c   Fuhr, Rainard ^d   Pascoe, Steve ^a  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Aster Cephac   (France)

^d PAREXEL INTERNATIONAL   (United States)

Author keywords

Asthma; Efficacy; Indacaterol; Safety; Salbutamol; Salmeterol; Single dose

Indexed keywords

BRONCHODILATING AGENT; INDACATEROL; PLACEBO; SALBUTAMOL; SALMETEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHITIS; BRONCHODILATATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; MORNING DOSAGE; NAUSEA; OPEN STUDY; POTASSIUM BLOOD LEVEL; PREDICTION; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VOMITING;

ADOLESCENT; ADULT; AGED; ALBUTEROL; ASTHMA; BLOOD GLUCOSE; BLOOD PRESSURE; BRONCHODILATOR AGENTS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; POTASSIUM; QUINOLONES; TREATMENT OUTCOME;

EID: 37749048011     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X242863     Document Type: Article

References (18)

1. 2-agonist therapy: a safety review of long-acting agents. Int J Clin Pract 2003;57:689-97
2. Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol 2002;110:S322-8
3. Brogden RN, Faulds D. Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42:895-912
4. Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993;48:611-14
5. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax 1992;47:30-3
6. Sykes AP, Ayres JG. A study of the duration of the bronchodilator effect of 12 micrograms and 24 micrograms of inhaled formoterol and 200 micrograms inhaled salbutamol in asthma. Respir Med 1990;84:135-8
7. 2-agonist, demonstrates 24-h efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Respir J 2005; 26 (Suppl. 49): 253s, P1729
8. Global Initiative for Asthma (GINA). NIH Publication 02-3659 issued January 1995 (updated 2002). At: http://www.ginasthma.com
9. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5-40
10. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18
11. Lotvall J, Langley S, Woodcock A. Inhaled steroid/long-acting beta 2 agonist combination products provide 24 h improvement in lung function in adult asthmatic patients. Respir Res 2006;7:110
12. Pauwels RA, Sears MR, Campbell M, et al.; RELIEF Study investigators. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787-94
13. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36
14. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24-h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study. Allergy; in press
15. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81
16. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1- hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006;317:762-70
17. 2- adrenoceptor agonists in asthma management. Respir Med 2005;99:152-70
18. Bennett JA, Tattersfield AE. Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 1997;52:458-64